Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma

Infectious Agents and Cancer

Volumn 3, Issue 1, 2008, Pages

  López Revilla, Rubén ^a   Martínez Contreras, Luz A ^a   Sánchez Garza, Mireya ^a  

^a INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ALGORITHM; ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER INVASION; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; HIGH RISK POPULATION; HISPANIC; HISTOLOGY; HUMAN; INFECTION PREVENTION; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

EID: 42149128157     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-3-3     Document Type: Article

References (46)

1. Estimates of the worldwide mortality from 25 cancers in 1990. P Pisani DM Parkin F Bray J Ferlay, Int J Cancer 1999 83 18 29 10.1002/(SICI)1097- 0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M 10449602
2. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. P Pisani F Bray DM Parkin, Int J Cancer 2002 97 72 81 10.1002/ijc.1571 11774246
3. Incidence and mortality of cervical cancer in Latin America. S Arrossi R Sankaranarayanan DM Parkin, Salud Publica Mex 2003 45 Suppl 3 S306 14 14746023
4. Human papillomavirus infection and cervical cancer in Latin America. WC Reeves LA Brinton M Garcia MM Brenes R Herrero E Gaitan F Tenorio RC de Britton WE Rawls, N Engl J Med 1989 320 1437 1441 2541336
5. Screening for cervical cancer in developing countries. MM Soe, Bmj 1992 304 983 984 1581735
6. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. EC Lazcano-Ponce S Moss P Alonso de Ruiz J Salmeron Castro M Hernandez Avila, Arch Med Res 1999 30 240 250 10.1016/S0188-0128(99)00006-8 10427875
7. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. LS Palacio-Mejia G Rangel-Gomez M Hernandez-Avila E Lazcano-Ponce, Salud Publica Mex 2003 45 Suppl 3 S315 25 14746024
8. Human papillomaviruses and their possible role in squamous cell carcinomas. H zur Hausen, Curr Top Microbiol Immunol 1977 78 1 30 202434
9. Papillomaviruses in human cancers. H Zur Hausen, Mol Carcinog 1988 1 147 150 10.1002/mc.2940010302 2855020
10. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 12 19 10.1002/(SICI)1096- 9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
11. High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus. P Volkow S Rubi M Lizano A Carrillo D Vilar-Compte A Garcia-Carranca R Sotelo B Garcia J Sierra-Madero A Mohar, Gynecol Oncol 2001 82 27 31 10.1006/gyno.2001.6244 11426958
12. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. N Munoz FX Bosch S de Sanjose A Vergara A del Moral MT Munoz L Tafur M Gili I Izarzugaza P Viladiu, Cancer Epidemiol Biomarkers Prev 1993 2 423 431 8220086
13. Classification of papillomaviruses. EM de Villiers C Fauquet TR Broker HU Bernard H zur Hausen, Virology 2004 324 17 27 10.1016/j.virol.2004.03.033 15183049
14. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Munoz FX Bosch S de Sanjose R Herrero X Castellsague KV Shah PJ Snijders CJ Meijer, N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259
15. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. FX Bosch MM Manos N Munoz M Sherman AM Jansen J Peto MH Schiffman V Moreno R Kurman KV Shah, J Natl Cancer Inst 1995 87 796 802 10.1093/jnci/87.11. 796 7791229
16. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Berumen RM Ordonez E Lazcano J Salmeron SC Galvan RA Estrada E Yunes A Garcia-Carranca G Gonzalez-Lira A Madrigal-de la Campa, J Natl Cancer Inst 2001 93 1325 1330 10.1093/jnci/93.17.1325 11535707
17. Tasa de mortalidad por cáncer cérvico uterino. Sistema para el Seguimiento de la Situación de la Mujer en México (SISESIM). http://dgcnesyp.inegi.gob.mx/sisesim/sisesim.html
18. Epidemiology of HPV infection among Mexican women with normal cervical cytology. E Lazcano-Ponce R Herrero N Munoz A Cruz KV Shah P Alonso P Hernandez J Salmeron M Hernandez, Int J Cancer 2001 91 412 420 10.1002/1097-0215(20010201) 91:3<412::AID-IJC1071>3.0.CO;2-M 11169968
19. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. Y Fujinaga M Shimada K Okazawa M Fukushima I Kato K Fujinaga, J Gen Virol 1991 72 ( Pt 5) 1039 1044 1851805
20. HPV prevalence among Mexican women with neoplastic and normal cervixes. M Torroella-Kouri S Morsberger A Carrillo A Mohar A Meneses M Ibarra RW Daniel AM Ghaffari G Solorza KV Shah, Gynecol Oncol 1998 70 115 120 10.1006/gyno.1998. 5055 9698486
21. Human papillomavirus and cancer: the epidemiological evidence. N Munoz, J Clin Virol 2000 19 1 5 10.1016/S1386-6532(00)00125-6 11091143
22. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. R Gonzalez-Losa Mdel I Rosado-Lopez N Valdez-Gonzalez M Puerto-Solis, J Clin Virol 2004 29 202 205 14962790
23. Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. J Berumen ER Unger L Casas P Figueroa, Hum Pathol 1995 26 676 681 10.1016/0046-8177(95)90175-2 7774900
24. Human papilloma virus 16-18 infection and cervical cancer in Mexico: a case-control study. M Hernandez-Avila EC Lazcano-Ponce J Berumen-Campos A Cruz-Valdez PP Alonso de Ruiz G Gonzalez-Lira, Arch Med Res 1997 28 265 271 9204620
25. Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis. JR Brody SE Kern, Biotechniques 2004 36 214 216 14989083
26. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. T Hwang, J Korean Med Sci 1999 14 593 599 10642935
27. Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. T Noda T Sasagawa Y Dong H Fuse M Namiki M Inoue, Urol Res 1998 26 165 169 10.1007/s002400050041 9694597
28. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. HU Bernard SY Chan MM Manos CK Ong LL Villa H Delius CL Peyton HM Bauer CM Wheeler, J Infect Dis 1994 170 1077 1085 7963696
29. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. TC Wright Jr. L Denny L Kuhn A Pollack A Lorincz, Jama 2000 283 81 86 10.1001/jama.283.1.81 10632284
30. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. GM Clifford RK Rana S Franceschi JS Smith G Gough JM Pimenta, Cancer Epidemiol Biomarkers Prev 2005 14 1157 1164 10.1158/1055-9965.EPI-04-0812 15894666
31. Human papillomavirus update with a particular focus on cervical disease. SM Garland, Pathology 2002 34 213 224 10.1080/00313020212469 12109780
32. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. M Molano A Van den Brule M Plummer E Weiderpass H Posso A Arslan CJ Meijer N Munoz S Franceschi, Am J Epidemiol 2003 158 486 494 10.1093/aje/kwg171 12936904
33. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. TM Becker CM Wheeler NS McGough CA Parmenter SW Jordan CA Stidley RS McPherson MH Dorin, Jama 1994 271 1181 1188 10.1001/jama.271.15.1181 8151876
34. Human papillomavirus testing methods. RA Hubbard, Arch Pathol Lab Med 2003 127 940 945 12873165
35. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. P Londesborough L Ho G Terry J Cuzick C Wheeler A Singer, Int J Cancer 1996 69 364 368 10.1002/(SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3 8900368
36. The natural history of type-specific human papillomavirus infections in female university students. H Richardson G Kelsall P Tellier H Voyer M Abrahamowicz A Ferenczy F Coutlee EL Franco, Cancer Epidemiol Biomarkers Prev 2003 12 485 490 12814991
37. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. CB Woodman S Collins H Winter A Bailey J Ellis P Prior M Yates TP Rollason LS Young, Lancet 2001 357 1831 1836 10.1016/S0140-6736(00)04956-4 11410191
38. Host and viral genetics and risk of cervical cancer: a review. A Hildesheim SS Wang, Virus Res 2002 89 229 240 10.1016/S0168-1702(02)00191-0 12445662
39. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. OM Williams KW Hart EC Wang CM Gelder, J Virol 2002 76 7418 7429 12097554 10.1128/JVI.76.15.7418-7429.2002
40. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. CM Corona Gutierrez A Tinoco T Navarro ML Contreras RR Cortes P Calzado L Reyes R Posternak G Morosoli ML Verde R Rosales, Hum Gene Ther 2004 15 421 431 10.1089/10430340460745757 15144573
41. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. LL Villa RL Costa CA Petta RP Andrade KA Ault AR Giuliano CM Wheeler LA Koutsky C Malm M Lehtinen FE Skjeldestad SE Olsson M Steinwall DR Brown RJ Kurman BM Ronnett MH Stoler A Ferenczy DM Harper GM Tamms J Yu L Lupinacci R Railkar FJ Taddeo KU Jansen MT Esser HL Sings AJ Saah E Barr, Lancet Oncol 2005 6 271 278 10.1016/S1470- 2045(05)70101-7 15863374
42. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). LE Markowitz EF Dunne M Saraiya HW Lawson H Chesson ER Unger, MMWR Recomm Rep 2007 56 1 24 17380109
43. Gardasil: Introducing the new human papillomavirus vaccine. MR McLemore, Clin J Oncol Nurs 2006 10 559 560 10.1188/06.CJON.559-560 17063609
44. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins D Jenkins A Schuind SA Costa Clemens G Dubin, Lancet 2006 367 1247 1255 10.1016/S0140-6736(06)68439-0 16631880
45. Analytical methods for evaluation on whole cells of human papillomavirus infection. Y Chardonnet G Lizard MC Chignol D Schmitt, Bull Cancer 1995 82 107 113 10846526
46. Detection and typing of human papillomavirus by e6 nested multiplex PCR. K Sotlar D Diemer A Dethleffs Y Hack A Stubner N Vollmer S Menton M Menton K Dietz D Wallwiener R Kandolf B Bultmann, J Clin Microbiol 2004 42 3176 3184 15243079 10.1128/JCM.42.7.3176-3184.2004